PLGA Carriers for Controlled Release of Levofloxacin in Anti-Tuberculosis Therapy

• Príomhchruthaitheoirí: Evgeny N. Antonov (Údar), Sofya N. Andreevskaya (Údar), Irina V. Bocharova (Údar), Sergei E. Bogorodsky (Údar), Larisa I. Krotova (Údar), Elena E. Larionova (Údar), Alexandra O. Mariyanats (Údar), Gennady V. Mishakov (Údar), Tatiana G. Smirnova (Údar), Larisa N. Chernousova (Údar), Vladimir K. Popov (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: MDPI AG, 2022-06-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

Levofloxacin (LFX) is a highly effective anti-tuberculosis drug with a pronounced bactericidal activity against <i>Mycobacterium tuberculosis</i> (<i>Mtb</i>). In this work, an "organic solvent-free" approach has been used for the development of polylactic-co-glycol...